Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$51.83
-2.3%
$55.87
$30.04
$71.13
$4.71B1.812.53 million shs1.59 million shs
Merus N.V. stock logo
MRUS
Merus
$65.84
-0.4%
$61.52
$33.19
$69.20
$4.98B1.19589,242 shs542,641 shs
Nuvalent, Inc. stock logo
NUVL
Nuvalent
$76.58
+0.7%
$78.55
$55.53
$113.51
$5.52B1.29435,414 shs418,360 shs
Schrodinger, Inc. stock logo
SDGR
Schrodinger
$19.51
-1.3%
$20.52
$16.60
$28.47
$1.44B1.791.39 million shs703,990 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
0.00%-4.58%-7.59%+40.27%+8.61%
Merus N.V. stock logo
MRUS
Merus
0.00%-2.44%+0.43%+12.49%+29.12%
Nuvalent, Inc. stock logo
NUVL
Nuvalent
0.00%+0.66%-1.52%-0.78%-10.04%
Schrodinger, Inc. stock logo
SDGR
Schrodinger
0.00%-3.99%-0.10%-10.05%-7.23%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
3.5771 of 5 stars
4.23.00.00.02.33.30.6
Merus N.V. stock logo
MRUS
Merus
2.0667 of 5 stars
3.51.00.00.02.82.50.0
Nuvalent, Inc. stock logo
NUVL
Nuvalent
3.3427 of 5 stars
4.51.00.00.03.73.30.0
Schrodinger, Inc. stock logo
SDGR
Schrodinger
3.102 of 5 stars
3.33.00.00.03.13.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
2.47
Hold$71.6038.14% Upside
Merus N.V. stock logo
MRUS
Merus
3.08
Buy$88.7534.80% Upside
Nuvalent, Inc. stock logo
NUVL
Nuvalent
3.09
Buy$120.8057.74% Upside
Schrodinger, Inc. stock logo
SDGR
Schrodinger
2.67
Moderate Buy$27.8342.66% Upside

Current Analyst Ratings Breakdown

Latest SDGR, NUVL, MRUS, and CRSP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/26/2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Zacks Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
8/25/2025
Merus N.V. stock logo
MRUS
Merus
Industrial Alliance Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$90.00
8/25/2025
Merus N.V. stock logo
MRUS
Merus
Alliance Global Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$90.00
8/19/2025
Nuvalent, Inc. stock logo
NUVL
Nuvalent
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$112.00
8/18/2025
Schrodinger, Inc. stock logo
SDGR
Schrodinger
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$28.00 ➝ $19.00
8/15/2025
Schrodinger, Inc. stock logo
SDGR
Schrodinger
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$35.00 ➝ $20.00
8/14/2025
Schrodinger, Inc. stock logo
SDGR
Schrodinger
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$25.00
8/14/2025
Schrodinger, Inc. stock logo
SDGR
Schrodinger
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$25.00
8/7/2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$65.00 ➝ $80.00
8/6/2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$42.00 ➝ $56.00
8/6/2025
Merus N.V. stock logo
MRUS
Merus
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
(Data available from 9/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$37.31M126.35N/AN/A$22.64 per share2.29
Merus N.V. stock logo
MRUS
Merus
$36.13M137.82N/AN/A$9.46 per share6.96
Nuvalent, Inc. stock logo
NUVL
Nuvalent
N/AN/AN/AN/A$14.99 per shareN/A
Schrodinger, Inc. stock logo
SDGR
Schrodinger
$207.54M6.92N/AN/A$5.78 per share3.38
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$366.25M-$5.43N/AN/AN/A-1,229.43%-20.05%-17.09%11/4/2025 (Estimated)
Merus N.V. stock logo
MRUS
Merus
-$215.33M-$5.50N/AN/AN/A-685.64%-50.28%-42.00%10/30/2025 (Estimated)
Nuvalent, Inc. stock logo
NUVL
Nuvalent
-$260.76M-$4.90N/AN/AN/AN/A-32.58%-30.14%11/11/2025 (Estimated)
Schrodinger, Inc. stock logo
SDGR
Schrodinger
-$187.12M-$2.48N/AN/AN/A-76.22%-45.70%-24.81%11/11/2025 (Estimated)

Latest SDGR, NUVL, MRUS, and CRSP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Nuvalent, Inc. stock logo
NUVL
Nuvalent
-$1.27-$1.31-$0.04-$1.39N/AN/A
8/6/2025Q2 2025
Schrodinger, Inc. stock logo
SDGR
Schrodinger
-$0.83-$0.59+$0.24-$0.59$52.03 million$54.76 million
8/5/2025Q1 2025
Merus N.V. stock logo
MRUS
Merus
-$1.17-$2.23-$1.06-$2.23$9.77 million$8.83 million
8/4/2025Q2 2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$1.47-$1.29+$0.18-$2.40$6.44 million$0.89 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
N/AN/AN/AN/AN/A
Merus N.V. stock logo
MRUS
Merus
N/AN/AN/AN/AN/A
Nuvalent, Inc. stock logo
NUVL
Nuvalent
N/AN/AN/AN/AN/A
Schrodinger, Inc. stock logo
SDGR
Schrodinger
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
N/A
16.61
16.61
Merus N.V. stock logo
MRUS
Merus
N/A
8.39
8.39
Nuvalent, Inc. stock logo
NUVL
Nuvalent
N/A
13.57
13.57
Schrodinger, Inc. stock logo
SDGR
Schrodinger
N/A
3.30
3.30

Institutional Ownership

CompanyInstitutional Ownership
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
69.20%
Merus N.V. stock logo
MRUS
Merus
96.14%
Nuvalent, Inc. stock logo
NUVL
Nuvalent
97.26%
Schrodinger, Inc. stock logo
SDGR
Schrodinger
79.05%

Insider Ownership

CompanyInsider Ownership
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
4.10%
Merus N.V. stock logo
MRUS
Merus
3.70%
Nuvalent, Inc. stock logo
NUVL
Nuvalent
10.20%
Schrodinger, Inc. stock logo
SDGR
Schrodinger
21.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
46090.95 million87.22 millionOptionable
Merus N.V. stock logo
MRUS
Merus
3775.63 million72.84 millionOptionable
Nuvalent, Inc. stock logo
NUVL
Nuvalent
4072.11 million64.75 millionOptionable
Schrodinger, Inc. stock logo
SDGR
Schrodinger
79073.61 million58.15 millionOptionable

Recent News About These Companies

Tema Etfs LLC Sells 18,331 Shares of Schrodinger, Inc. $SDGR
AlphaQuest LLC Trims Holdings in Schrodinger, Inc. $SDGR
Schrödinger: A Complex Story With Many Moving Parts
Schrodinger (SDGR) Gets a Buy from Barclays
Craig-Hallum Sticks to Its Buy Rating for Schrodinger (SDGR)

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRISPR Therapeutics stock logo

CRISPR Therapeutics NASDAQ:CRSP

$51.83 -1.22 (-2.30%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$51.80 -0.03 (-0.06%)
As of 08/29/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Merus stock logo

Merus NASDAQ:MRUS

$65.84 -0.26 (-0.39%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$65.84 +0.00 (+0.01%)
As of 08/29/2025 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Nuvalent stock logo

Nuvalent NASDAQ:NUVL

$76.58 +0.56 (+0.74%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$76.60 +0.02 (+0.02%)
As of 08/29/2025 04:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Schrodinger stock logo

Schrodinger NASDAQ:SDGR

$19.51 -0.25 (-1.27%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$19.52 +0.00 (+0.03%)
As of 08/29/2025 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.